Anti-mouse/rat MHC Class II (I-Ek/RT1-D) (Clone 14-4-4S (HB-32)) – PE

C3H mouse skin graft and splenocytes

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)

14-4-4S (HB-32) activity is directed against mouse MHC Class II alloantigen I-Ek and rat MHC Class II alloantigen RT1-D. In mouse, 14-4-4S cross-reacts with H-2k, H-2d, H-2p, and H-2r and is specific to Ia.7 in the Ia chart. 14-4-4S also recognizes a cell surface marker on hamster B lymphocytes.

H-2, the murine major histocompatibility complex (MHC), is composed of a diverse group of antigens divided into class I and II proteins that function in immune response¹. Class II molecules, also known as Ia antigens, regulate recognition of foreign antigens on the surfaces of antigen presenting cells and play a major role in the mixed lymphocyte response². Mice have two class II isotypes, I-A and I-E, each of which is a glycoprotein composed of an ⍺ and β Subunit.

14-4-4S was generated by immunizing C3H.SW mice with spleen cells from C3H mice³. The resulting spleen cells were then fused with Sp2/0-Ag14 myeloma cells for hybridoma generation. Further studies have found that whole 14-4-4S antibody and F(ab’)₂ fragments block RT1-D-restricted Ag presentation as well as activation of an I-Eʹ-restricted T cell hybridoma in vitro⁴.

Additionally, because 14-4-4S recognizes hamster B cells, 14-4-4S can be used in hamster to deplete B cells and enrich for T cells via flow cytometry⁵ or by removing adherent B lymphocytes in immunoglobulin-coated tissue culture dishes⁶.

I-Ek and RT1-D are expressed primarily on the surface of B lymphocytes, antigen-presenting cells, macrophages, dendritic cells, and a subset of T cells.

CD3/TCR, CD4

1 Yoshida R. Adv Immunol. 124:207-247. 2014.
2 Spencer JS, Kubo RT. J Exp Med. 169(3):625-460. 1989.
3 Ozato K, Mayer N, Sachs DH. J Immunol. 124(2):533-540. 1980.
4 Haag S, Tuncel J, Thordardottir S, et al. J Immunol. 194(6):2539-2350. 2015.
5 Liu H, Steiner BM, Alder JD, et al. Infect Immun. 58(6):1685-1690. 1990.
6 Lim LC, England DM, DuChateau BK, et al. Infect Immun. 63(4):1400-1408. 1995.
7 Shih FF, Racz J, Allen PM. J Immunol. 176(6):3438-3448. 2006.
8 Epstein SL, Ozato K, Bluestone JA, et al. J Exp Med. 154(2):397-409. 1981.
9 Turkewitz AP, Sullivan CP, Mescher MF. Mol Immunol. 20(11):1139-1147. 1983.
10 Maloy WL, Ozato K, Sachs DH, et al. Mol Immunol. 23(3):263-269. 1986.
11 Farr A, DeRoos PC, Eastman S, et al. Eur J Immunol. 26(12):3185-3193. 1996.
12 Desmet C, Gosset P, Pajak B, et al. J Immunol. 173(9):5766-5775. 2004.
13 Holmberg D, Forsgren S, Forni L, et al. Proc Natl Acad Sci U S A. 81(10):3175-3179. 1984.
14 Isobe M, Narula J, Southern JF, et al. Circulation. 85(2):738-746. 1992.